These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15446778)

  • 1. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Offord R; Lloyd AC; Anderson P; Bearne A
    Pharm World Sci; 2004 Aug; 26(4):214-20. PubMed ID: 15446778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.
    Reeves P; Cooke J; Lloyd A; Hutchings A
    Pharm World Sci; 2004 Jun; 26(3):160-8. PubMed ID: 15230364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
    Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
    Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
    McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
    Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
    de Lissovoy G; Subedi P
    Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin.
    Turpie AG; Norris TM
    Thromb Haemost; 2004 Jul; 92(1):3-12. PubMed ID: 15213839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
    Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
    Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
    Etchells E; McLeod RS; Geerts W; Barton P; Detsky AS
    Arch Intern Med; 1999 Jun; 159(11):1221-8. PubMed ID: 10371230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice.
    McGarry LJ; Thompson D
    Clin Ther; 2004 Mar; 26(3):419-30. PubMed ID: 15110135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD; Goeree R; Crowther MA; O'Brien BJ
    Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 17652767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.
    Shorr AF; Ramage AS
    Crit Care Med; 2001 Sep; 29(9):1659-65. PubMed ID: 11546959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty.
    Dunn CJ; Goa KL
    Pharmacoeconomics; 1996 Aug; 10(2):179-90. PubMed ID: 10163420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of the MEDENOX trial: a Canadian perspective. Medical Patients with Enoxaparin.
    Lamy A; Wang X; Kent R; Smith KM; Gafni A
    Can Respir J; 2002; 9(3):169-77. PubMed ID: 12068338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes.
    Bergqvist D
    Pharmacoeconomics; 2002; 20(4):225-43. PubMed ID: 11950380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
    Argenta C; Ferreira MA; Sander GB; Moreira LB
    Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness analysis of enoxaparin for the prophylaxis of venous thromboembolism in major orthopedic surgery patients].
    Brosa Riestra M; Rubio-Terrés C; Nadipelli V; Casado Collado A; Martínez Brotons F
    Farm Hosp; 2003; 27(4):210-8. PubMed ID: 12966450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients in Spain.
    Nuijten MJ; Villar FA; Kosa J; Nadipelli V; Rubio-Terrés C; Suarez C
    Value Health; 2003; 6(2):126-36. PubMed ID: 12641863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
    Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
    Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease.
    Nicholson T; McGuire A; Milne R
    BMC Cardiovasc Disord; 2001; 1():2. PubMed ID: 11701090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.